# B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

> **NCT04483778** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Seattle Children's Hospital** · enrollment: 68 (estimated)

## Conditions studied

- Pediatric Solid Tumor
- Germ Cell Tumor
- Retinoblastoma
- Hepatoblastoma
- Wilms Tumor
- Rhabdoid Tumor
- Carcinoma
- Osteosarcoma
- Ewing Sarcoma
- Rhabdomyosarcoma
- Synovial Sarcoma
- Clear Cell Sarcoma
- Malignant Peripheral Nerve Sheath Tumors
- Desmoplastic Small Round Cell Tumor
- Soft Tissue Sarcoma
- Neuroblastoma
- Melanoma

## Interventions

- **BIOLOGICAL:** second generation 4-1BBζ B7H3-EGFRt-DHFR
- **BIOLOGICAL:** second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04483778
- **Lead sponsor:** Seattle Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-07-13
- **Primary completion:** 2040-12
- **Final completion:** 2040-12
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04483778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04483778, "B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04483778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*